- $43.45bn
- $47.25bn
- $9.91bn
- 83
- 25
- 56
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.52 | ||
| PEG Ratio (f) | 0.59 | ||
| EPS Growth (f) | 75.79% | ||
| Dividend Yield (f) | 0.42% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.97 | ||
| Price to Tang. Book | 12.62 | ||
| Price to Free Cashflow | 29.9 | ||
| Price to Sales | 4.38 | ||
| EV to EBITDA | 18.16 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.26% | ||
| Return on Equity | 5.23% | ||
| Operating Margin | 15.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6,833 | 8,291 | 8,717 | 9,455 | 9,911 | 10,477.68 | 11,247.96 | 5.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -90.33 | +706.92 | -49.89 | +343.33 | +17.71 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
Directors
- F. Michael Ball CHM (65)
- David Endicott CEO (55)
- D. Keith Grossman VCH (61)
- Timothy Stonesifer CFO (52)
- Ian Bell CEX (50)
- Leon Duplan Fraustro CEX (53)
- Rajkumar Narayanan CEX (56)
- Sue-Jean Lin SVP
- Laurent Attias OTH (53)
- Arthur Cummings DRC (58)
- Lynn Bleil IND (57)
- Thomas Glanzmann IND (62)
- Scott Maw IND (54)
- Karen May IND (62)
- Ines Poeschel IND (52)
- Dieter Spaelti IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 21st, 2018
- Public Since
- April 9th, 2019
- No. of Employees
- 25,599
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 494,600,000
- Address
- Rue Louis d'Affry 6, FRIBOURG, 1700
- Web
- https://www.alcon.ch/
- Phone
- Contact
- Dan Cravens
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ALC
Upcoming Events for ALC
Half Year 2025 Alcon AG Earnings Release
Half Year 2025 Alcon AG Earnings Call
Q3 2025 Alcon AG Earnings Release
Q3 2025 Alcon AG Earnings Call
Similar to ALC
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
Avantor
New York Stock Exchange
FAQ
As of Today at 19:09 UTC, shares in Alcon AG are trading at $87.78. This share price information is delayed by 15 minutes.
Shares in Alcon AG last closed at $87.78 and the price had moved by -0.4% over the past 365 days. In terms of relative price strength the Alcon AG share price has underperformed the S&P500 Index by -10.96% over the past year.
The overall consensus recommendation for Alcon AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Alcon AG dividend yield is 0.35% based on the trailing twelve month period.
Last year, Alcon AG paid a total dividend of $0.31, and it currently has a trailing dividend yield of 0.35%. We do not have any data on when Alcon AG is to next pay dividends.
We do not have data on when Alcon AG is to next pay dividends. The historic dividend yield on Alcon AG shares is currently 0.35%.
To buy shares in Alcon AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $87.78, shares in Alcon AG had a market capitalisation of $43.45bn.
Here are the trading details for Alcon AG:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ALC
Based on an overall assessment of its quality, value and momentum Alcon AG is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alcon AG is $106.65. That is 21.5% above the last closing price of $87.78.
Analysts covering Alcon AG currently have a consensus Earnings Per Share (EPS) forecast of $3.15 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alcon AG. Over the past six months, its share price has outperformed the S&P500 Index by +0.2%.
As of the last closing price of $87.78, shares in Alcon AG were trading -2.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alcon AG PE ratio based on its reported earnings over the past 12 months is 25.52. The shares last closed at $87.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alcon AG's management team is headed by:
- F. Michael Ball - CHM
- David Endicott - CEO
- D. Keith Grossman - VCH
- Timothy Stonesifer - CFO
- Ian Bell - CEX
- Leon Duplan Fraustro - CEX
- Rajkumar Narayanan - CEX
- Sue-Jean Lin - SVP
- Laurent Attias - OTH
- Arthur Cummings - DRC
- Lynn Bleil - IND
- Thomas Glanzmann - IND
- Scott Maw - IND
- Karen May - IND
- Ines Poeschel - IND
- Dieter Spaelti - IND